Martin Brunner

Summary

Affiliation: Medical University of Vienna
Country: Austria

Publications

  1. ncbi request reprint Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans
    Martin Brunner
    Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics, Institute of Medical and Chemical Laboratory Diagnostics, Vienna, Austria
    Clin Pharmacol Ther 78:182-90. 2005
  2. ncbi request reprint Combined PET and microdialysis for in vivo assessment of intracellular drug pharmacokinetics in humans
    Oliver Langer
    Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics, Medical University of Vienna, Vienna, Austria
    J Nucl Med 46:1835-41. 2005
  3. pmc [18F]Ciprofloxacin, a new positron emission tomography tracer for noninvasive assessment of the tissue distribution and pharmacokinetics of ciprofloxacin in humans
    Martin Brunner
    Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics, Medical University of Vienna, Allgemeines Krankenhaus, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Antimicrob Agents Chemother 48:3850-7. 2004
  4. ncbi request reprint In vitro and in vivo evaluation of [18F]ciprofloxacin for the imaging of bacterial infections with PET
    Oliver Langer
    Division of Clinical Pharmacokinetics, Department of Clinical Pharmacology, Medical University Vienna, Wahringer Gurtel 18 20, 1090, Vienna, Austria
    Eur J Nucl Med Mol Imaging 32:143-50. 2005
  5. ncbi request reprint Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[(11)C]verapamil
    Oliver Langer
    Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics, Medical University of Vienna, Vienna, Austria
    Epilepsia 48:1774-84. 2007
  6. ncbi request reprint A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer's disease
    Martin Bauer
    Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics, University of Vienna, Vienna, Austria
    Clin Pharmacol Ther 80:216-27. 2006
  7. ncbi request reprint Synthesis of fluorine-18-labeled ciprofloxacin for PET studies in humans
    Oliver Langer
    Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics, Vienna University Medical School, Vienna, Austria
    Nucl Med Biol 30:285-91. 2003
  8. pmc A new topical formulation enhances relative diclofenac bioavailability in healthy male subjects
    Martin Brunner
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    Br J Clin Pharmacol 71:852-9. 2011
  9. pmc Microdialysis versus other techniques for the clinical assessment of in vivo tissue drug distribution
    Martin Brunner
    Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics, Medical University of Vienna Allgemeines Krankenhaus, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    AAPS J 8:E263-71. 2006
  10. pmc Favourable dermal penetration of diclofenac after administration to the skin using a novel spray gel formulation
    Martin Brunner
    Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics, Medical University of Vienna, Allgemeines Krankenhaus AKH, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Br J Clin Pharmacol 60:573-7. 2005

Collaborators

Detail Information

Publications32

  1. ncbi request reprint Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans
    Martin Brunner
    Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics, Institute of Medical and Chemical Laboratory Diagnostics, Vienna, Austria
    Clin Pharmacol Ther 78:182-90. 2005
    ....
  2. ncbi request reprint Combined PET and microdialysis for in vivo assessment of intracellular drug pharmacokinetics in humans
    Oliver Langer
    Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics, Medical University of Vienna, Vienna, Austria
    J Nucl Med 46:1835-41. 2005
    ....
  3. pmc [18F]Ciprofloxacin, a new positron emission tomography tracer for noninvasive assessment of the tissue distribution and pharmacokinetics of ciprofloxacin in humans
    Martin Brunner
    Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics, Medical University of Vienna, Allgemeines Krankenhaus, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Antimicrob Agents Chemother 48:3850-7. 2004
    ..In this way, the frequent use of ciprofloxacin for the treatment of a variety of infections could be corroborated...
  4. ncbi request reprint In vitro and in vivo evaluation of [18F]ciprofloxacin for the imaging of bacterial infections with PET
    Oliver Langer
    Division of Clinical Pharmacokinetics, Department of Clinical Pharmacology, Medical University Vienna, Wahringer Gurtel 18 20, 1090, Vienna, Austria
    Eur J Nucl Med Mol Imaging 32:143-50. 2005
    ..The suitability of the 18F-labelled fluoroquinolone antibiotic ciprofloxacin ([18F]ciprofloxacin) for imaging of bacterial infections with positron emission tomography (PET) was assessed in vitro and in vivo...
  5. ncbi request reprint Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[(11)C]verapamil
    Oliver Langer
    Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics, Medical University of Vienna, Vienna, Austria
    Epilepsia 48:1774-84. 2007
    ..We compared R-[(11)C]verapamil kinetics in homologous brain volumes of interest (VOIs) located ipsilateral and contralateral to the seizure focus...
  6. ncbi request reprint A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer's disease
    Martin Bauer
    Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics, University of Vienna, Vienna, Austria
    Clin Pharmacol Ther 80:216-27. 2006
    ....
  7. ncbi request reprint Synthesis of fluorine-18-labeled ciprofloxacin for PET studies in humans
    Oliver Langer
    Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics, Vienna University Medical School, Vienna, Austria
    Nucl Med Biol 30:285-91. 2003
    ..A series of analytical tests was performed in order to prove the identity of the radiolabeled compound and its suitability for human applications...
  8. pmc A new topical formulation enhances relative diclofenac bioavailability in healthy male subjects
    Martin Brunner
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    Br J Clin Pharmacol 71:852-9. 2011
    ....
  9. pmc Microdialysis versus other techniques for the clinical assessment of in vivo tissue drug distribution
    Martin Brunner
    Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics, Medical University of Vienna Allgemeines Krankenhaus, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    AAPS J 8:E263-71. 2006
    ..Used alone or in combination, these methods may potentially play an important role in future drug research and development with the potential to serve as translational tools for clinical decision making...
  10. pmc Favourable dermal penetration of diclofenac after administration to the skin using a novel spray gel formulation
    Martin Brunner
    Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics, Medical University of Vienna, Allgemeines Krankenhaus AKH, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Br J Clin Pharmacol 60:573-7. 2005
    ....
  11. pmc Concentrations of gemifloxacin at the target site in healthy volunteers after a single oral dose
    Florian Islinger
    Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics, Medical University of Vienna, Allgemeines Krankenhaus, Waehringer Guertel 18 20, 1090 Vienna, Austria
    Antimicrob Agents Chemother 48:4246-9. 2004
    ..Therefore, based on pharmacokinetic and pharmacodynamic calculations, we conclude that gemifloxacin might be a useful therapeutic option for the treatment of soft tissue infections...
  12. doi request reprint CYP2C9 genotype and association with bone mineral density: a pilot study
    Sophie Brunner-Ziegler
    Division of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria
    Gene 526:295-8. 2013
    ..The aim of the present investigation was to clarify a potential role of CYP2C9 sequence variations and susceptibility to develop osteoporosis...
  13. ncbi request reprint Simultaneous analysis of MDR1 C3435T, G2677T/A, and C1236T genotypes by multiplexed mutagenically separated PCR
    Raute Sunder-Plassmann
    Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, Vienna, Austria
    Clin Chem Lab Med 43:192-4. 2005
    ..This newly developed MDR1 MS-PCR will facilitate fast, accurate and economic analysis of MDR1 genotypes and will provide important information in optimizing individual therapeutic approaches...
  14. ncbi request reprint Microdialysis for in vivo pharmacokinetic/pharmacodynamic characterization of anti-infective drugs
    Martin Brunner
    Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Curr Opin Pharmacol 5:495-9. 2005
    ..Furthermore, microdialysis might contribute to the definition of meaningful surrogate markers for antibiotic efficiency during drug development...
  15. ncbi request reprint Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease
    Sophie Ziegler
    Department of Internal Medicine II, Vienna General Hospital, Medical University of Vienna, Austria
    Stroke 36:1394-9. 2005
    ..We tested for an association of gene sequence variations in P2Y12 and occurrence of neurological adverse events in patients with symptomatic peripheral artery disease (PAD) during clopidogrel treatment...
  16. doi request reprint A randomised, two-period, cross-over, open-label study to evaluate the pharmacokinetic profiles of single doses of two different flurbiprofen 8.75-mg lozenges in healthy volunteers
    Peter Matzneller
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    Pharmacology 89:188-91. 2012
    ..To compare the bioavailability of a new oromucosal formulation of flurbiprofen 8.75-mg lozenges, developed by Alfa Wassermann S.p.A. (test drug) to that of marketed flurbiprofen 8.75-mg lozenges (Benactiv Gola®, reference drug)...
  17. doi request reprint Forearm vasodilator reactivity in homozygous carriers of the 9p21.3 rs1333049 G>C polymorphism
    Stefan Aschauer
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    Eur J Clin Invest 40:700-5. 2010
    ..The aim of the present case-control study was to test whether this chromosome 9p21.3 locus, represented by the rs1333049 variant, is associated with altered vasodilator resistance vessel function in healthy young volunteers...
  18. ncbi request reprint Pharmacodynamics of piperacillin in severely ill patients evaluated by using a PK/PD model
    Robert Sauermann
    Department of Clinical Pharmacology, University of Vienna, Vienna General Hospital, Wahringer Gurtel 18 20, A 1090, Vienna, Austria
    Int J Antimicrob Agents 22:574-8. 2003
    ..This finding is due to impaired renal function and subsequently prolonged tissue and plasma half-lives of piperacillin in intensive care patients...
  19. doi request reprint Ramipril modulates circadian gene expression in skeletal muscle
    Robert Sauermann
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    Pharmacogenet Genomics 21:751-9. 2011
    ..To identify these mechanisms, we studied the effect of ACE-inhibition on gene expression in skeletal muscle, a primary target tissue for insulin in glucose homeostasis...
  20. pmc An exploratory microdialysis study investigating the effect of repeated application of a diclofenac epolamine medicated plaster on prostaglandin concentrations in skeletal muscle after standardized physical exercise
    Angela Burian
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    Br J Clin Pharmacol 76:880-7. 2013
    ....
  21. doi request reprint Disposition and metabolism of safinamide, a novel drug for Parkinson's disease, in healthy male volunteers
    Chiara Leuratti
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    Pharmacology 92:207-16. 2013
    ....
  22. ncbi request reprint Wine ingestion has no effect on lipid peroxidation products
    Sophie Ziegler
    Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics, Medical University Vienna, Vienna, Austria
    Pharmacology 75:152-6. 2005
    ..Thus, the present study was carried out to determine the acute effects of different wines on LDL oxidization in healthy volunteers...
  23. doi request reprint Plasma pharmacokinetics and gastrointestinal transit of a new propionyl-L-carnitine controlled release formulation
    Claudia C Wagner
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    Xenobiotica 41:988-95. 2011
    ..A daily dose of 500 mg to 1000 mg PLC twice a day was well tolerated, justifying further studies in patients with pathologies of the distal gastrointestinal tract to evaluate the efficacy of the MMX-PLC formulation...
  24. pmc Target site concentrations of ciprofloxacin after single intravenous and oral doses
    Martin Brunner
    Department of Clinical Pharmacology, University of Vienna Medical School, Austria
    Antimicrob Agents Chemother 46:3724-30. 2002
    ..These differences, however, are not related to a difference in target site pharmacodynamics...
  25. doi request reprint Lisinopril pharmacokinetics and erythropoietin requirement in haemodialysis patients
    Wolfgang Winnicki
    Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria
    Eur J Clin Invest 42:1087-93. 2012
    ..However, it is unknown whether or not plasma levels or area under the curve (AUC) of ACE-I are associated with responsiveness to ESA therapy...
  26. ncbi request reprint Influence of systemic inflammation on the interpretation of response to antiplatelet therapy, monitored by PFA-100
    Sophie Ziegler
    Clinical Department of Angiology, Medical University of Vienna, Vienna, Austria
    Semin Thromb Hemost 31:416-9. 2005
    ..With respect to the response to antiplatelet therapy with ASA, the results suggest that the platelet inhibitory effect of ASA is not reduced under inflammatory conditions...
  27. ncbi request reprint Microdialysis: an in vivo approach for measuring drug delivery in oncology
    Martin Brunner
    Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics, University of Vienna Medical School, Allgemeines Krankenhaus, Wahringer Gurtel 18 20, 1090 Vienna, Austria
    Eur J Clin Pharmacol 58:227-34. 2002
    ....
  28. ncbi request reprint Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by in vivo microdialysis
    Olaf Burkhardt
    Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, USA
    J Antimicrob Chemother 58:632-6. 2006
    ..Microdialysis and plasma samples were collected before and at different time points up to 12 h after medication. Drug concentrations were determined by a validated LC-MS-MS method...
  29. pmc Factors influencing blood pressure response to trandolapril add-on therapy in patients taking verapamil SR (from the International Verapamil SR/Trandolapril [INVEST] Study)
    Martin Brunner
    Department of Pharmacy Practice, College of Pharmacy, University of Florida, Gainesville, USA
    Am J Cardiol 99:1549-54. 2007
    ..Race was associated with diastolic BP response, although the difference is likely not to be clinically significant and AGTR1 genotype was not associated with BP response...
  30. pmc Penetration of fosfomycin into the parenchyma of human brain: a case study in three patients
    Martin Brunner
    Br J Clin Pharmacol 54:548-50. 2002
  31. ncbi request reprint [Therapeutic implications of polymorphisms in cytochromes and drug transporters]
    Eva Münster
    Universitätsklinik für Klinische Pharmakologie, Medizinische Universität Wien, Wien, Osterreich
    Wien Med Wochenschr 155:54-8. 2005
    ..In the future, genetic screening by genotyping before the initiation of pharmacotherapy might help to identify responders or non-responders and might it offer individualized therapies to select patient populations...
  32. ncbi request reprint Comparative target site pharmacokinetics of immediate- and modified-release formulations of cefaclor in humans
    la Peña Amparo de
    Department of Pharmaceutics, University of Florida, Gainesville 32610, USA
    J Clin Pharmacol 42:403-11. 2002
    ..The data of the present study indicate that time above MIC values at the target site can be substantially prolonged if an antibiotic is administered as a sustained-release product...